Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome
Erik J.M. van Bommel, Marcel H.A. Muskiet, Lennart Tonneijck, et al.
Clinical Journal of the American Society of Nephrology (2017) Vol. 12, Iss. 4, pp. 700-710
Open Access | Times Cited: 204

Showing 26-50 of 204 citing articles:

High glucose couples DJ-1 with PTEN to activate PDGFRβ for renal proximal tubular cell injury
Falguni Das, Nandini Ghosh‐Choudhury, Balakuntalam S. Kasinath, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0311828-e0311828
Open Access | Times Cited: 1
Can SGLT2 Inhibitors Cause Acute Renal Failure? Plausible Role for Altered Glomerular Hemodynamics and Medullary Hypoxia
Auryan Szalat, Amichai Perlman, Mordechai Muszkat, et al.
Drug Safety (2017) Vol. 41, Iss. 3, pp. 239-252
Closed Access | Times Cited: 83
Treatment of Hyperuricemia in Chronic Kidney Disease
Juan C. Ramírez‐Sandoval, Magdalena Madero
Contributions to nephrology (2018), pp. 135-146
Closed Access | Times Cited: 71
Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes
Erik J.M. van Bommel, Hilde Herrema, Mark Davids, et al.
Diabetes & Metabolism (2019) Vol. 46, Iss. 2, pp. 164-168
Closed Access | Times Cited: 67
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial
Takashi Kadowaki, Masaomi Nangaku, Stefan Hantel, et al.
Journal of Diabetes Investigation (2018) Vol. 10, Iss. 3, pp. 760-770
Open Access | Times Cited: 66
Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD
Andrew S. Allegretti, Wenbin Zhang, Wenjiong Zhou, et al.
American Journal of Kidney Diseases (2019) Vol. 74, Iss. 3, pp. 328-337
Open Access | Times Cited: 66
Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
Soghra Rabizadeh, Manouchehr Nakhjavani, Alireza Esteghamati
International Journal of Endocrinology and Metabolism (2019) Vol. In Press, Iss. In Press
Open Access | Times Cited: 57
The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
Ken Ohara, Takahiro Masuda, Masato Morinari, et al.
Diabetology & Metabolic Syndrome (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 52
Sodium–glucose cotransporter 2 inhibitors and risk of nephrolithiasis
Kasper Bruun Kristensen, Daniel Pilsgaard Henriksen, Jesper Hallas, et al.
Diabetologia (2021) Vol. 64, Iss. 7, pp. 1563-1571
Open Access | Times Cited: 46
Oxidative Stress Induced by Lipotoxicity and Renal Hypoxia in Diabetic Kidney Disease and Possible Therapeutic Interventions: Targeting the Lipid Metabolism and Hypoxia
Seung Yun Chae, Yaeni Kim, Cheol Whee Park
Antioxidants (2023) Vol. 12, Iss. 12, pp. 2083-2083
Open Access | Times Cited: 21
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis
Fernando Caravaca‐Fontán, Kate Stevens, Maite Padrón, et al.
Nephrology Dialysis Transplantation (2023) Vol. 39, Iss. 2, pp. 328-340
Open Access | Times Cited: 19
Nephroprotective Properties of Antidiabetic Drugs
Christian Gerdes, N Müller, Günter Wolf, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 10, pp. 3377-3377
Open Access | Times Cited: 17
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies
Natalie McCormick, Chio Yokose, Na Lu, et al.
BMJ (2024), pp. e080035-e080035
Open Access | Times Cited: 6
Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study
Eu Jeong Ku, Dong‐Hwa Lee, Hyun Jeong Jeon, et al.
Diabetes Research and Clinical Practice (2019) Vol. 151, pp. 65-73
Closed Access | Times Cited: 53
Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes
André Scheen
Diabetes & Metabolism (2018) Vol. 45, Iss. 2, pp. 110-121
Closed Access | Times Cited: 49
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Charlotte M. Mosterd, Petter Bjornstad, Daniël H. van Raalte
Journal of Nephrology (2020) Vol. 33, Iss. 5, pp. 965-975
Open Access | Times Cited: 45
Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes
Seshagiri Rao Nandula, Nabanita Kundu, Hassan Awal, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 41
SGLT2 inhibitors: a narrative review of efficacy and safety
Donald S. Nelinson, José Manuel Sosa, Robert Ćhilton
Journal of Osteopathic Medicine (2021) Vol. 121, Iss. 2, pp. 229-239
Open Access | Times Cited: 41
Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan
Mu‐Chi Chung, Peir‐Haur Hung, Po‐Jen Hsiao, et al.
JAMA Network Open (2021) Vol. 4, Iss. 11, pp. e2135353-e2135353
Open Access | Times Cited: 38
The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture
Bingzi Dong, Ruolin Lv, Jun Wang, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 24
SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases
Assunta Di Costanzo, Giovanni Esposito, Ciro Indolfi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8732-8732
Open Access | Times Cited: 16
Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan
Mu‐Chi Chung, Peir‐Haur Hung, Po‐Jen Hsiao, et al.
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e230453-e230453
Open Access | Times Cited: 14
Sodium-Glucose Cotransporter-2 Inhibitors and Cardiovascular Protection Among Patients With Type 2 Diabetes Mellitus: A Systematic Review
Richard K Yankah, Eric Komla Anku, Vinay Eligar
Journal of Diabetes Research (2024) Vol. 2024, pp. 1-9
Open Access | Times Cited: 6
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Alfredo Caturano, Raffaele Galiero, Maria Rocco, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 2039-2039
Open Access | Times Cited: 6
Diabetic patients with essential hypertension treated with amlodipine
Agustín J. Ramiréz, María José Sánchez, Ramiro Sánchez
Journal of Hypertension (2018) Vol. 37, Iss. 3, pp. 636-642
Closed Access | Times Cited: 42

Scroll to top